Postoperative analgesic efficacy and safety of imrecoxib versus celecoxib in hip osteoarthritis patients undergoing total hip arthroplasty: a multi-center, randomized, controlled, non-inferiority study.

研究概要

156 patients undergoing total hip arthroplasty (THA) for hip osteoarthritis were randomized to receive either celecoxib (n=78) or imrecoxib (n=78). Outcomes of interest included pain at rest and with movement on a Visual Analog Scale (VAS), opioid consumption, Harris Hip Scores (HHS), quality of life on the EuroQol 5 Dimensions (EQ-5D) questionnaire, and the incidence of adverse events, all measured until postoperative day 7. Non-inferiority was tested between the two groups. No significant differences in resting and movement VAS pain scores were apparent between the two groups at all time points. Similarly, there were no differences in opioid consumption, HHS, EQ-5D, and adverse events between the two groups at all time points.